KRAS and pancreatic neoplasm: Erastin was initially described as a potent cytotoxic drug against RAS mutant cancers [10], and as KRAS mutations are found in more than 90% of pancreatic cancer patients [38], we hypothesized that an Erastin-based therapy would work effectively if we could overcome the uptake blockade observed in pancreatic cancer cells.